Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

By afschroeder • April 1, 2026

Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma. Future Oncol. 2026 Mar 31:1-19. doi: 10.1080/14796694.2026.2643481. Epub ahead of print. PMID: 41914670.

Tags: binimetinib, BRAF V600, Encorafenib, Hematology/Oncology, LOGIC 2, melanoma, plain language summary, Publications, third drug

RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial

Chugh R, Singh A, Andelkovic V, Mallick AB, Brockstein B, Bui N, Chawla S, Choy E, Davis LE, Gounder M, Haddadin S, Kasper B, Kim[...]

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

Padula WV, Cohen BG, Steel P, Appukkuttan S, Kalayeh B, Rettig M. Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer:[...]

tRNA dosage regulates lineage dependency and resistance in prostate cancer

Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk[...]